ContraFect Corporation, a New York-based biotech company targeting bacterial infections and infectious diseases such as drug-resistant Staphyloccus (MRSA) and Influenza. Led by Founder, Dr. Robert C. Nowinski, ContraFect had positioned itself as a transformative company within the marketplace by pioneering the use of recombinant proteins for the treatment of drug-resistant bacteria.
Dr. Nowinski had much success building similar ventures, establishing seven previous companies and bringing four of those companies public through IPO financing. The current worth of these companies are valued in the billions. Nevertheless, Dr. Nowinski met with FNM Capital Funding during the early stages of this start-up to discuss financing. With the assistance of Maxim Group, FNM Capital Funding, and a few other private investors, Dr. Nowinski and ContraFect raised more than $15 million in financing in 2010 and 2011. This first round of funding will help ContraFect in the research and development of their first products with a vision for IPO in May 2012.
YONKERS, NY–(Marketwire -12/14/11)- ContraFect Corporation, the company that is pioneering the use of recombinant proteins for the treatment of drug-resistant bacteria, completed a face-to-face pre-IND (Investigational New Drug) meeting with the FDA on December 9, 2011 to discuss the development plans for CF-301, a biologic antimicrobial therapy for acute bacterial skin and skin structure infections. CF-301 is a first-in-class investigational drug with potential to have a major role in the treatment of infections caused by MRSA (drug-resistant staphylococcus) and streptococcus. information about domain The FDA addressed the Company’s questions and provided guidance on the requirements to file an IND to initiate clinical trials. The IND is expected to be submitted mid-2012.
YONKERS, NY–(Marketwire -11/15/11)- ContraFect Corporation, the company that is pioneering the use of recombinant proteins for the treatment of drug-resistant bacteria, announced today that David Huang, M.D., Ph.D. has joined as its Chief Medical Officer. As CMO, Dr. Huang will be responsible for the company’s clinical strategy and the development of its lead compound, CF-301, for infections caused by Staphylococcus and Streptococcus. CF-301 is a first-in-class drug that is expected to have a major role in the treatment of infections caused by MRSA (drug-resistant Staphylococcus).